This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           September 24, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Maintenance pazopanib in ovarian cancer: No survival benefit
Cancer Network (Free login required)
Maintenance therapy with the oral agent pazopanib improved progression free survival by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III randomized trial reported in the Journal of Clinical Oncology.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


2015 SGO International Scholar Travel Grants deadline Oct. 25
SGO
SGO is offering three International Scholar Travel Grants to assist multidisciplinary early career professionals involved in the prevention, research, treatment or care of gynecologic cancers. Scholarship applications are being accepted now through Oct. 25. The scholarship provides up to $3,300 USD for travel and lodging expenses to attend the SGO Annual Meeting on Women's Cancer® in Chicago, Illinois, March 28-31, 2015.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


OVARIAN CANCER


Endpoints for studies of ovarian cancer
MedPage Today
The time-tested approach of a phase III clinical trial comparing drug A versus drug B has become largely infeasible relative to the myriad of legitimate options based on rapid target discovery, and in the current regulatory environment such investigations are becoming prohibitively costly, time-consuming and are unable to adjust to new discoveries during the course of the trial. This dynamic has placed a premium on reassessing our clinical trials strategy and developing meaningful clinical trial endpoints.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


MORCELLATION


Gynecologists resist FDA over popular surgical tool
The Wall Street Journal (Subscription required)
Doctors nationwide are still using a gynecological tool months after the U.S. Food and Drug Administration warned that it can spread undetected cancer, demonstrating the limits of the regulator's reach into clinical practice.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


CHEMOTHERAPY


Exercise boosts tumor-fighting ability of chemotherapy, team finds
ScienceDaily
Study after study has proven it true: exercise is good for you. But new research suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy. Their work, performed in a mouse model of melanoma, found that combining exercise with chemotherapy shrunk tumors more than chemotherapy alone.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
MORE


HEALTH POLICY


Terminally ill, but constantly hospitalized
NPR
New York and New Jersey are home to 12 of the 25 regions where chronically-ill patients are hospitalized longest in their last six months of life in 2011. The reasons they do this are many, but most experts agree that it has less to do with the unique characteristics and desires of people in New York and New Jersey than the health care system and culture that has evolved here.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




GENETICS


Finding risks, not answers, in gene tests
The New York Times (Subscription required)
Cases of frightening or confusing results from genetic tests are becoming more common because of a big recent change in genetic testing for cancer risk. Competing companies have hugely expanded the array of tests they offer, in part because new technology has made it possible to sequence many genes for the same price as one or two.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


VULVAR CANCER


UPMC study: Adding chemotherapy to radiation treatment not effective in treating vulvar cancer
Medical News Today
The addition of chemotherapy to post-surgical radiation treatment is not effective in treating vulvar cancer, according to Magee-Womens Hospital of UPMC research presented recently in San Francisco at the 56th annual meeting of the American Society for Radiation Oncology. Led by Dr. Sushil Beriwal, associate professor with the department of radiation oncology at the University of Pittsburgh School of Medicine and radiation oncologist at Magee, this study identified patients diagnosed with vulvar cancer between 1998 and 2011 who had undergone surgery to remove the cancer and required adjuvant radiation therapy because the disease had spread to their lymph nodes.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Sept. 17, 2014
Sept. 10, 2014
Sept. 3, 2014
Aug. 20, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063